company background image
ARDX logo

Ardelyx NasdaqGM:ARDX 株式レポート

最終価格

US$4.71

時価総額

US$1.1b

7D

-26.2%

1Y

16.9%

更新

14 Nov, 2024

データ

会社財務 +

Ardelyx, Inc.

NasdaqGM:ARDX 株式レポート

時価総額:US$1.1b

ARDX 株式概要

バイオ医薬品企業であるアーデリクス社は、消化器系および循環器系の治療領域を対象とした医薬品の発見、開発、商業化を米国内外で行っている。 詳細

ARDX ファンダメンタル分析
スノーフレーク・スコア
評価5/6
将来の成長5/6
過去の実績0/6
財務の健全性5/6
配当金0/6

Ardelyx, Inc. 競合他社

価格と性能

の歴代最高値、変動、値下がりまとめArdelyx
過去の株価
現在の株価US$4.71
52週高値US$10.13
52週安値US$3.83
ベータ0.91
11ヶ月の変化-21.11%
3ヶ月変化-19.49%
1年変化16.87%
33年間の変化376.77%
5年間の変化-26.52%
IPOからの変化-66.62%

最新ニュース

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Nov 14

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Oct 24
Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Recent updates

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Nov 14

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Oct 24
Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Aug 25
Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 07
Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Ardelyx Faces Rising Challenges Despite Revenue Growth

Aug 05

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 04
Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Jul 13

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Jul 05
Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Ardelyx: Strong Execution, Fairly Valued

May 10

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04
Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

May 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17
Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Jan 31

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Jan 10

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Jan 04
Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Dec 14
Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03
Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31
Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17
Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30
Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14
Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

What To Expect For Ardelyx In The Coming Month

Oct 18

株主還元

ARDXUS BiotechsUS 市場
7D-26.2%-2.4%1.0%
1Y16.9%22.2%33.1%

業界別リターン: ARDX過去 1 年間で22.2 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: ARDXは、過去 1 年間で33.1 % のリターンを上げたUS市場を下回りました。

価格変動

Is ARDX's price volatile compared to industry and market?
ARDX volatility
ARDX Average Weekly Movement9.9%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.0%

安定した株価: ARDXの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: ARDXの weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
2007267Mike Raabwww.ardelyx.com

バイオ医薬品企業である Ardelyx, Inc.は、消化器系および循環器系の治療領域を対象とした医薬品の発見、開発、商業化を米国内外で行っている。同社の主力製品候補は、便秘を伴う過敏性腸症候群の治療薬テナパノールである。また、透析を受けている慢性腎臓病(CKD)の成人患者(高リン血症)の血清リンを低下させることを目的とした第III相臨床試験中のXPHOZAH、腎不全や心不全の患者で問題となる血清カリウム上昇(高カリウム血症)の治療薬であるカリウム分泌促進薬RDX013、重篤な電解質異常である代謝性アシドーシスの成人患者を対象としたRDX020も開発している。同社は協和キリン、佛山医薬工業開発有限公司、ナイト・セラピューティクスと契約を結んでいる。Ltd.、Knight Therapeutics, Inc.と、それぞれの地域におけるテナパノールの開発および商業化に関する契約を締結している。同社は以前Nteryx, Inc.として知られていたが、2008年6月に社名をArdelyx, Inc.に変更した。Ardelyx, Inc.は2007年に法人化され、マサチューセッツ州ウォルサムに本社を置いている。

Ardelyx, Inc. 基礎のまとめ

Ardelyx の収益と売上を時価総額と比較するとどうか。
ARDX 基礎統計学
時価総額US$1.07b
収益(TTM)-US$72.58m
売上高(TTM)US$251.85m

4.4x

P/Sレシオ

-15.4x

PER(株価収益率

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
ARDX 損益計算書(TTM)
収益US$251.85m
売上原価US$85.54m
売上総利益US$166.31m
その他の費用US$238.89m
収益-US$72.58m

直近の収益報告

Sep 30, 2024

次回決算日

該当なし

一株当たり利益(EPS)-0.31
グロス・マージン66.03%
純利益率-28.82%
有利子負債/自己資本比率79.0%

ARDX の長期的なパフォーマンスは?

過去の実績と比較を見る